DP 2221
Alternative Names: 225Ac-PSMA-TTM; DP-2221; ITM-22Latest Information Update: 28 Jul 2024
At a glance
- Originator Isotopen Technologien Munchens
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Prostate-cancer in USA (Parenteral)
- 24 Jun 2021 Phase-I clinical trials in Prostate cancer in USA (Parenteral) (Isotopien Technologien Munhens pipeline, May 2021)
- 24 Jun 2021 Preclinical trials in Prostate cancer in USA (Parenteral) (Isotopien Technologien Munhens pipeline, May 2021)